JEDDAH, 19 November 2003 — “Snafi,” an anti-impotence drug, has hit the United Arab Emirates market after its registration and approval by the UAE Ministry of Health.
“Spimaco has reached a commercial and technical agreement with Eli-Lilly and Company. The accord entitles ‘Spimaco’ to have the rights to market ‘tadalafil,’ the latest innovation approved for treatment of erectile dysfunction in males. This agreement envisages an exchange of cooperation at technical, medical training and marketing levels for promoting tadalafil,” Spimaco Managing Director Dr. Abdullah Al-Abdulkader said.
“This is considered the first agreement of its kind related to tadalafil,” he said, adding that Spimaco was the first pharmaceutical corporation worldwide that was granted the rights for manufacturing under its brand name “Snafi”.
“Clinical studies of this product have proven to produce a desired effect within 16 to 30 minutes and last for more than 24 hours. Snafi doesn’t negatively interact with food. It is considered effective and safe for patients with diabetes and hypertension.” Snafi is available in 20mg tablets.
Spimaco entered the UAE market several years ago and established a scientific office there to market its products, which are in great demand and enjoy high reputation for their quality.
